Alexion Pharma (ALXN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Alexion Reports First Quarter 2016 Results
April 28, 2016 6:30 AM EDTTotal Revenues of $701 Million; Increased 17 Percent Year-on-Year; 22 Percent Increase Year-on-Year on a Constant Currency Basis
Soliris® (eculizumab) Revenues Driven by Steady Number of New Patients Treated in the U.S., Europe and Japan
Strensiq® (asfotase alfa) Launch Off to a Strong Start in Initial Countries
Kanuma® (sebelipase alfa) U.S. Launch Under Way
Exceeded Target Enrollment for Two Initial Studies of ALXN1210 in Patients with PNH
Commenced Dose Escalation for SBC-103 in Phase 1/2 Study in Patients with MPS IIIB
Progressed Three Registration Studies... More
